PMID- 17169625
OWN - NLM
STAT- MEDLINE
DCOM- 20070130
LR  - 20181201
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 98
IP  - 12A
DP  - 2006 Dec 18
TI  - Evolving management of ST-segment elevation myocardial infarction: update on 
      recent data.
PG  - 10Q-21Q
AB  - Significant recent advances have been made in strategies for managing ST-segment 
      elevation myocardial infarction (STEMI). Based on new findings, the American 
      College of Cardiology (ACC) and the American Heart Association (AHA) have updated 
      their guidelines for acute myocardial infarction (MI) with newer recommendations 
      for STEMI management. Many of these recommendations focus on antithrombotic 
      agents, with a movement toward lower doses of long-term aspirin and lower doses 
      of unfractionated heparin (UFH). Studies have also been completed on the use of 
      enoxaparin and fondaparinux as potential alternatives to heparin, and clinical 
      trial data support the early use of glycoprotein IIb/IIIa inhibitors (along with 
      aspirin, UFH, and clopidogrel) in patients undergoing primary percutaneous 
      coronary intervention for acute STEMI. Clopidogrel has also been shown to improve 
      angiographic and clinical outcomes in patients with STEMI who are undergoing 
      thrombolysis or being treated medically. The new ACC/AHA recommendations support 
      clopidogrel pretreatment and long-term therapy.
FAU - Cannon, Christopher P
AU  - Cannon CP
AD  - Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular 
      Division, Department of Medicine, Brigham and Women's Hospital and Harvard 
      Medical School, Boston, Massachusetts 02115, USA. cpcannon@partners.org
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20061107
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 9005-49-6 (Heparin)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angioplasty, Balloon, Coronary
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Clopidogrel
MH  - Fibrinolytic Agents/therapeutic use
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Myocardial Infarction/physiopathology/*prevention & control
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Practice Guidelines as Topic
MH  - Societies, Medical
MH  - Thrombolytic Therapy
MH  - Ticlopidine/analogs & derivatives/therapeutic use
MH  - United States
RF  - 33
EDAT- 2006/12/16 09:00
MHDA- 2007/01/31 09:00
CRDT- 2006/12/16 09:00
PHST- 2006/12/16 09:00 [pubmed]
PHST- 2007/01/31 09:00 [medline]
PHST- 2006/12/16 09:00 [entrez]
AID - S0002-9149(06)01742-5 [pii]
AID - 10.1016/j.amjcard.2006.09.026 [doi]
PST - ppublish
SO  - Am J Cardiol. 2006 Dec 18;98(12A):10Q-21Q. doi: 10.1016/j.amjcard.2006.09.026. 
      Epub 2006 Nov 7.